189 related articles for article (PubMed ID: 17101320)
1. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
Bonkovsky HL; Naishadham D; Lambrecht RW; Chung RT; Hoefs JC; Nash SR; Rogers TE; Banner BF; Sterling RK; Donovan JA; Fontana RJ; Di Bisceglie AM; Ghany MG; Morishima C;
Gastroenterology; 2006 Nov; 131(5):1440-51. PubMed ID: 17101320
[TBL] [Abstract][Full Text] [Related]
2. Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.
Gehrke SG; Stremmel W; Mathes I; Riedel HD; Bents K; Kallinowski B
J Mol Med (Berl); 2003 Dec; 81(12):780-7. PubMed ID: 14557859
[TBL] [Abstract][Full Text] [Related]
3. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C.
Geier A; Reugels M; Weiskirchen R; Wasmuth HE; Dietrich CG; Siewert E; Gartung C; Lorenzen J; Bosserhoff AK; Brügmann M; Gressner AM; Matern S; Lammert F
Liver Int; 2004 Aug; 24(4):285-94. PubMed ID: 15287851
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C, iron status, and disease severity: relationship with HFE mutations.
Tung BY; Emond MJ; Bronner MP; Raaka SD; Cotler SJ; Kowdley KV
Gastroenterology; 2003 Feb; 124(2):318-26. PubMed ID: 12557137
[TBL] [Abstract][Full Text] [Related]
5. HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis.
Ladero JM; Ropero P; Ortega L; Taxonera C; González FA; López-Alonso G; Briceño O; Rodríguez-Agulló JL; González L; Villegas A; Díaz-Rubio M
Rev Esp Enferm Dig; 2003 Dec; 95(12):829-36. PubMed ID: 14972004
[TBL] [Abstract][Full Text] [Related]
6. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations.
Piperno A; Vergani A; Malosio I; Parma L; Fossati L; Ricci A; Bovo G; Boari G; Mancia G
Hepatology; 1998 Oct; 28(4):1105-9. PubMed ID: 9755249
[TBL] [Abstract][Full Text] [Related]
7. The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C.
Carneiro MV; Souza FF; Teixeira AC; Figueiredo JF; Villanova MG; Secaf M; Passos AD; Ramalho LN; Carneiro FP; Zucoloto S; Candolo Martinelli AL
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1204-10. PubMed ID: 20555268
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.
Ishizu Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
J Gastroenterol Hepatol; 2012 Jun; 27(6):1112-6. PubMed ID: 22098610
[TBL] [Abstract][Full Text] [Related]
9. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
Sikorska K; Stalke P; Izycka-Swieszewska E; Romanowski T; Bielawski KP
Med Sci Monit; 2010 Mar; 16(3):CR137-143. PubMed ID: 20190684
[TBL] [Abstract][Full Text] [Related]
10. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.
Erhardt A; Maschner-Olberg A; Mellenthin C; Kappert G; Adams O; Donner A; Willers R; Niederau C; Häussinger D
J Hepatol; 2003 Mar; 38(3):335-42. PubMed ID: 12586300
[TBL] [Abstract][Full Text] [Related]
11. The H63D mutation of the hemochromatosis gene is associated with sustained virological response in chronic hepatitis C patients treated with interferon-based therapy: a meta-analysis.
Li SH; Zhao H; Ren YY; Liu YZ; Song G; Ding P; Ding YP; Wang GQ
Tohoku J Exp Med; 2012 Apr; 226(4):293-9. PubMed ID: 22499121
[TBL] [Abstract][Full Text] [Related]
12. Iron overload and HFE gene mutations in Polish patients with liver cirrhosis.
Sikorska K; Romanowski T; Stalke P; Iżycka-Świeszewska E; Bielawski KP
Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):270-5. PubMed ID: 21669570
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan.
Mah YH; Kao JH; Liu CJ; Chen CL; Chen PJ; Lai MY; Chen DS
Liver Int; 2005 Apr; 25(2):214-9. PubMed ID: 15780041
[TBL] [Abstract][Full Text] [Related]
14. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity.
Chitturi S; Weltman M; Farrell GC; McDonald D; Kench J; Liddle C; Samarasinghe D; Lin R; Abeygunasekera S; George J
Hepatology; 2002 Jul; 36(1):142-9. PubMed ID: 12085358
[TBL] [Abstract][Full Text] [Related]
15. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C.
Bonkovsky HL; Troy N; McNeal K; Banner BF; Sharma A; Obando J; Mehta S; Koff RS; Liu Q; Hsieh CC
J Hepatol; 2002 Dec; 37(6):848-54. PubMed ID: 12445428
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection.
Toll A; Celis R; Ozalla MD; Bruguera M; Herrero C; Ercilla MG
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1201-6. PubMed ID: 17062032
[TBL] [Abstract][Full Text] [Related]
17. Iron overload and HFE gene mutations in Czech patients with chronic liver diseases.
Dostalikova-Cimburova M; Kratka K; Stransky J; Putova I; Cieslarova B; Horak J
Dis Markers; 2012; 32(1):65-72. PubMed ID: 22297603
[TBL] [Abstract][Full Text] [Related]
18. Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C.
Lebray P; Zylberberg H; Hue S; Poulet B; Carnot F; Martin S; Chretien Y; Pol S; Caillat-Zuckman S; Bréchot C; Nalpas B
J Viral Hepat; 2004 Mar; 11(2):175-82. PubMed ID: 14996353
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of HFE mutations and relation to serum iron status in patients with chronic hepatitis C and patients with nonalcoholic fatty liver disease in Taiwan.
Lin TJ; Lin CL; Wang CS; Liu SO; Liao LY
World J Gastroenterol; 2005 Jul; 11(25):3905-8. PubMed ID: 15991291
[TBL] [Abstract][Full Text] [Related]
20. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.
Valenti L; Fracanzani AL; Bugianesi E; Dongiovanni P; Galmozzi E; Vanni E; Canavesi E; Lattuada E; Roviaro G; Marchesini G; Fargion S
Gastroenterology; 2010 Mar; 138(3):905-12. PubMed ID: 19931264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
